BEDFORD, Mass–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Jonathan Talamo, M.D., Chief Medical Officer, will present at the Ophthalmology Innovation Summit (OIS) at the American Society of Retina Specialists (ASRS) on Monday, August 8, 2016, in San Francisco, CA. Dr. Talamo will provide an update on the Company’s ongoing
At Retina 2016, David Sarraf, MD, compares type 1 and type 3 neovascularization visualized by OCT angiography in patients with age-related macular degeneration.
A research team headed by investigators at the Icahn School of Medicine at Mount Sinai has developed a tool that allows scientists to quickly manipulate levels of two proteins in the same cell.
One- and two-year-old children are at the highest risk of burning their eyes with chemicals, despite the long held belief that working-age adults were the most at risk from this type of severe eye injury, new Johns Hopkins Bloomberg School of Public He…
The majority of patients with Fuchs’ endothelial corneal dystrophy who underwent Descemet’s membrane endothelial keratoplasty showed an improvement in color discernment scores after surgery, according to a study. The prospective, single-center study included 26 eyes of 26 patients with Fuchs’ endothelial corneal dystrophy who underwent DMEK; 24 eyes were pseudophakic and two eyes were phakic.
New research from University College London, Moorfields Eye Hospital and Duke University School of Medicine has identified a gene that drives scarring, together with a rapidly translatable therapy, for the UK’s most common cause of blinding conjunctivi…